Published in J Virol on August 19, 2009
Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A (2010) 12.39
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Deep sequencing of the vaginal microbiota of women with HIV. PLoS One (2010) 2.59
Evaluation of methods for the extraction and purification of DNA from the human microbiome. PLoS One (2012) 2.34
The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome (2014) 2.24
Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A (2009) 2.13
Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol (2012) 1.94
HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS (2010) 1.76
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev (2011) 1.65
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol (2011) 1.55
Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. Immunol Cell Biol (2014) 1.46
Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest (2011) 1.44
Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One (2013) 1.43
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J Biol Chem (2010) 1.26
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Association between Trichomonas vaginalis and vaginal bacterial community composition among reproductive-age women. Sex Transm Dis (2012) 1.20
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
Comparison of storage conditions for human vaginal microbiome studies. PLoS One (2012) 1.14
Barriers to mucosal transmission of immunodeficiency viruses. Blood (2011) 1.14
Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One (2013) 1.13
Cell-to-cell transmission of viruses. Curr Opin Virol (2012) 1.13
Biological hydrogels as selective diffusion barriers. Trends Cell Biol (2011) 1.10
Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules (2012) 1.08
Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol (2015) 1.07
Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS (2010) 1.05
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater (2012) 1.05
Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One (2012) 1.03
IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol (2014) 1.02
Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota. MBio (2015) 1.02
Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol (2015) 1.00
Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One (2011) 0.99
Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J Immunol (2010) 0.97
Preventing HIV infection in women. J Acquir Immune Defic Syndr (2013) 0.95
Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Antiviral Res (2010) 0.90
Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV. J Infect Dis (2014) 0.90
The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases. Virulence (2016) 0.89
Nanoparticle-based flow virometry for the analysis of individual virions. J Clin Invest (2013) 0.88
Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion. Biophys J (2014) 0.87
Autophagy and HIV. Semin Cell Dev Biol (2010) 0.87
Dual role of commensal bacteria in viral infections. Immunol Rev (2013) 0.87
Glycosphingolipid-functionalized nanoparticles recapitulate CD169-dependent HIV-1 uptake and trafficking in dendritic cells. Nat Commun (2014) 0.87
Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol (2012) 0.86
Viruses and the Microbiota. Annu Rev Virol (2015) 0.86
Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. Adv Drug Deliv Rev (2015) 0.86
Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro. AAPS J (2013) 0.85
Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV. MAbs (2014) 0.85
Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. PLoS One (2014) 0.84
Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials (2011) 0.84
Innate and acquired immunity in the human penile urethra. J Reprod Immunol (2011) 0.82
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH. Biomacromolecules (2013) 0.82
Maternal Microbiome and Pregnancy Outcomes That Impact Infant Health: A Review. Adv Neonatal Care (2015) 0.81
Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus. ACS Infect Dis (2015) 0.81
Advances in HIV microbicide development. Future Med Chem (2011) 0.81
HIV-1 vaginal transmission: cell-free or cell-associated virus? Am J Reprod Immunol (2014) 0.81
Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: a workshop summary. AIDS Res Hum Retroviruses (2012) 0.80
Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle tracking. PLoS One (2012) 0.80
Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus. Acta Biomater (2016) 0.79
An adsorption chromatography assay to probe bulk particle transport through hydrogels. J Pharm Sci (2011) 0.79
Associations between vaginal pathogenic community and bacterial vaginosis in Chinese reproductive-age women. PLoS One (2013) 0.78
Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation. ACS Nano (2016) 0.78
Minimizing biases associated with tracking analysis of submicron particles in heterogeneous biological fluids. J Control Release (2015) 0.78
Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion. Biophys J (2015) 0.77
Surface Transmission or Polarized Egress? Lessons Learned from HTLV Cell-to-Cell Transmission. Viruses (2010) 0.77
Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1. Mol Biol Int (2012) 0.77
Imaging endocervical mucus anatomy and dynamics in macaque female reproductive track using optical coherence tomography. Quant Imaging Med Surg (2015) 0.77
Bacterial vaginosis among women at high risk for HIV in Uganda: high rate of recurrent diagnosis despite treatment. Sex Transm Infect (2015) 0.77
Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo. Antimicrob Agents Chemother (2015) 0.76
Theaflavin-3,3'-digallate and lactic acid combinations reduce herpes simplex virus infectivity. Antimicrob Agents Chemother (2013) 0.76
Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. J Control Release (2014) 0.76
Thermosensitive and mucoadhesive pluronic-hydroxypropylmethylcellulose hydrogel containing the mini-CD4 M48U1 is a promising efficient barrier against HIV diffusion through macaque cervicovaginal mucus. Antimicrob Agents Chemother (2015) 0.76
Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules (2014) 0.75
Modeling of Virion Collisions in Cervicovaginal Mucus Reveals Limits on Agglutination as the Protective Mechanism of Secretory Immunoglobulin A. PLoS One (2015) 0.75
Responsive foams for nanoparticle delivery. Colloids Surf B Biointerfaces (2015) 0.75
Diffusion of Immunoglobulin G in Shed Vaginal Epithelial Cells and in Cell-Free Regions of Human Cervicovaginal Mucus. PLoS One (2016) 0.75
Increases in Endogenous or Exogenous Progestins Promote Virus-Target Cell Interactions within the Non-human Primate Female Reproductive Tract. PLoS Pathog (2016) 0.75
Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus? Virol J (2017) 0.75
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol (2000) 4.87
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A (2007) 3.94
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev (2008) 3.41
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
Micro- and macrorheology of mucus. Adv Drug Deliv Rev (2009) 2.54
Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun (1999) 2.42
Target cells in vaginal HIV transmission. Microbes Infect (2003) 2.36
Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev (2005) 2.21
The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses (1998) 2.12
Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med (1991) 2.04
Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology (2006) 1.97
T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis (1997) 1.85
What's new in bacterial vaginosis and trichomoniasis? Infect Dis Clin North Am (2005) 1.83
In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol (1997) 1.69
HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A (2005) 1.67
Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol (2008) 1.52
A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm Dis (2003) 1.40
Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis (2003) 1.38
Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS One (2009) 1.37
Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil (1973) 1.30
Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis (2005) 1.26
Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol (2000) 1.26
Preventing sexual transmission of HIV. Clin Infect Dis (2007) 1.16
Leukocytes migrate through three-dimensional gels of midcycle cervical mucus. Cell Immunol (1994) 0.99
Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS Patient Care STDS (1999) 0.98
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science (2003) 6.22
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A (2007) 3.94
Actin is part of pre-initiation complexes and is necessary for transcription by RNA polymerase II. Nat Cell Biol (2004) 3.43
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A (2006) 3.43
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev (2008) 3.41
Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog (2007) 2.75
Micro- and macrorheology of mucus. Adv Drug Deliv Rev (2009) 2.54
Efficient active transport of gene nanocarriers to the cell nucleus. Proc Natl Acad Sci U S A (2003) 2.52
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl (2008) 2.38
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol (2006) 2.32
Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev (2005) 2.21
HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep (2009) 2.18
Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A (2009) 2.13
Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci U S A (2011) 2.08
Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.06
Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem (2003) 2.01
Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology (2006) 1.97
MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res (2010) 1.94
Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol (2008) 1.88
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A (2009) 1.86
A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med (2012) 1.85
Keratinization of the adult male foreskin and implications for male circumcision. AIDS (2010) 1.85
A functional anatomic defect of the cystic fibrosis airway. Am J Respir Crit Care Med (2014) 1.85
Epidemic Lymphogranuloma venereum during epidemics of crack cocaine use and HIV infection in the Bahamas. Sex Transm Dis (2002) 1.79
Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem (2002) 1.79
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood (2010) 1.72
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol (2007) 1.65
Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev (2011) 1.65
Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials (2007) 1.59
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials (2009) 1.54
MRI-detectable pH nanosensors incorporated into hydrogels for in vivo sensing of transplanted-cell viability. Nat Mater (2013) 1.53
Greentree white paper: sexual violence, genitoanal injury, and HIV: priorities for research, policy, and practice. AIDS Res Hum Retroviruses (2012) 1.52
HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (2009) 1.49
Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2003) 1.48
Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol (2007) 1.47
TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell (2007) 1.47
Biophysics: is rhodopsin dimeric in native retinal rods? Nature (2003) 1.43
Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS One (2009) 1.37
Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A (2013) 1.36
Gene therapy of endothelial nitric oxide synthase and manganese superoxide dismutase restores delayed wound healing in type 1 diabetic mice. Circulation (2004) 1.36
Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons. Exp Biol Med (Maywood) (2007) 1.31
Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol (2013) 1.31
Localization of CD4 and CCR5 in living cells. J Virol (2003) 1.28
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials (2002) 1.27
Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology (2010) 1.23
Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl (2011) 1.23
The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int (2013) 1.21
PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine (2007) 1.20
Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog (2004) 1.20
Real-time intracellular transport of gene nanocarriers studied by multiple particle tracking. Biotechnol Prog (2004) 1.19
Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. Mol Cell Biol (2005) 1.18
Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events. J Virol (2004) 1.17
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One (2010) 1.12
Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials (2013) 1.11
New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS (2013) 1.09
CRM1-dependent function of a cis-acting RNA export element. Mol Cell Biol (2002) 1.09
Live cell imaging of the HIV-1 life cycle. Trends Microbiol (2008) 1.08
Unclosed HIV-1 capsids suggest a curled sheet model of assembly. J Mol Biol (2012) 1.08
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol (2011) 1.07
Characterization of the intracellular dynamics of a non-degradative pathway accessed by polymer nanoparticles. J Control Release (2007) 1.07
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater (2012) 1.05
Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials (2011) 1.04
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology (2008) 1.04
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux. J Virol (2006) 1.04
Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c. Am J Physiol Endocrinol Metab (2008) 1.04
Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release (2011) 1.03
Role of the cytoskeleton in nuclear import. Adv Drug Deliv Rev (2003) 1.03
Mobility of human immunodeficiency virus type 1 Pr55Gag in living cells. J Virol (2006) 1.03
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release (2004) 1.02
Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) (2011) 1.01
The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virol J (2006) 1.01